Skip to main content
SpringerLink
Log in

Lymphocyte-Predominant Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1109 Accesses

Abstract

Lymphocyte-predominant Hodgkin lymphoma (LPHL) was first described in 1944 by Jackson and Parker as nodular paragranuloma [1]. Other synonyms used were lymphocytic predominant Hodgkin disease, lymphocytic and histiocytic (L&H) predominant Hodgkindisease, nodular lymphocyte-predominant Hodgkin disease, and nodular LPHL [2–5]. This term has become the one that is currently being used. LPHL represents 5% of all HL cases and is a rare disease with an estimated incidence of 1.5 per million [6]. LPHL differs from classical Hodgkin lymphoma in pathological and clinical characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jackson H, Parker F. Hodgkin’s disease II. Pathology. N Engl J Med. 1944;231.

    Google Scholar 

  2. Lukes R, Butler J, Hicks E. Natural history of Hodgkin’s disease as related to its pathological picture. Cancer. 1966;19:317.

    Article  Google Scholar 

  3. Harris NL, Jaffe JS, Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361.

    PubMed  CAS  Google Scholar 

  4. Jaffe E, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001. p. 240–3.

    Google Scholar 

  5. Swerdlow SH, Campo E, Harris ES, Jaffe NL, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva: WHO Press; 2008.

    Google Scholar 

  6. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte predominant Hodgkin’s disease: report from the European Task Force on Lymphoma (ETFL) Project on lymphocyte-predominant hodgkin’s disease. J Clin Oncol. 1999;17:776–83.

    PubMed  CAS  Google Scholar 

  7. Mason DY, Banks PM, Chan J, et al. Nodular lymphocyte-predominance Hodgkin’s disease. A distinct clinicopathological entity. Am J Surg Pathol. 1994;18:526–30.

    Article  PubMed  CAS  Google Scholar 

  8. Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102:3753–8.

    Article  PubMed  CAS  Google Scholar 

  9. Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed–Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B-cells at various stages of development. Proc Natl Acad Sci USA. 1994;91:10962–6.

    Article  PubMed  Google Scholar 

  10. Delabie J, Tierens A, Wu G, et al. Lymphocyte predominance Hodgkin’s disease: lineage and clonality determination using a single-cell assay. Blood. 1994;84:3291–8.

    PubMed  CAS  Google Scholar 

  11. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal center B-cells. N Engl J Med. 1997;337:453–8.

    Article  PubMed  CAS  Google Scholar 

  12. Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin’s disease. N Engl J Med. 1997;337:459–65.

    Article  PubMed  CAS  Google Scholar 

  13. Schumacher AM, Schmitz R, Brune V, et al. Mutations in the genes coding for den NJ-κB regulation factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin lymphoma. Haematologica. 2010;95:153–7.

    Article  PubMed  CAS  Google Scholar 

  14. Rüdiger TO, Ott MM, Müller-Deubert SM, et al. Differential diagnosis between classical Hodgkin’s lymphoma, T-cell-rich B-cell lymphoma and paragranuloma by paraffin immunochemistry. Am J Surg Pathol. 1998;22:1184–91.

    Article  PubMed  Google Scholar 

  15. Poppema S. The nature of the lymphocytes surrounding Reed–Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin’s disease. Am J Pathol. 1989;135:351–7.

    PubMed  CAS  Google Scholar 

  16. Felgar RE, Steward KR, Cousar JB, et al. T-cell-rich large B-cell lymphomas contain non-activated CD8+ cytolytic T-cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas. Am J Pathol. 1998;153:1707–15.

    Article  PubMed  CAS  Google Scholar 

  17. Alkan S, Ross CW, Hanson CA, et al. Epstein–Barr virus and BCL-2 protein overexpression are not detected in the neoplastic cells of nodular lymphocyte predominance Hodgkin’s disease. Mod Pathol. 1995;8:544–7.

    PubMed  CAS  Google Scholar 

  18. Torlakovic E, Tierens A, Dang HD, et al. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin’s disease. Am J Pathol. 2001;159:1807–14.

    Article  PubMed  CAS  Google Scholar 

  19. Sundeen JT, Gossman J, Jaffe ES. Lymphocyte predominant Hodgkin’s disease nodular subtype with coexistent “large cell lymphoma”. Histological progression or composite malignancy? Am J Surg Pathol. 1988;12:599–606.

    PubMed  CAS  Google Scholar 

  20. Huang JZ, Weisenburger DD, Vose JM, et al. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma. 2004;45:1551–7.

    Article  PubMed  Google Scholar 

  21. Rüdiger T, Gascoyne RE, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin’s lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Ann Oncol. 2002;13 suppl 1:44–51.

    Article  PubMed  Google Scholar 

  22. Greiner TC, Gascoyne RD, Anderson ME, et al. Nodular lymphocyte-predominant Hodgkin’s disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood. 1996;88:657–66.

    PubMed  CAS  Google Scholar 

  23. Shimabukuru-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin’s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin’s Study Group trials. J Clin Oncol. 2005;23:5739–45.

    Article  Google Scholar 

  24. Henry-Amar M. Second cancer after treatment for Hodgkin’s disease: a report from the International Database on Hodgkin’s disease. Ann Oncol. 1992;3 suppl 4:117.

    Article  PubMed  Google Scholar 

  25. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte predominant Hodgkin lymphoma: long-term results of a phase 2 trial of the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109–11.

    Article  PubMed  CAS  Google Scholar 

  26. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26:434–9.

    Article  PubMed  Google Scholar 

  27. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin’s lymphoma in children: therapeutic abstention after initial lymph node resection – a study of the French Society of Pediatric Oncology. J Clin Oncol. 2003;21:2948–52.

    Article  PubMed  CAS  Google Scholar 

  28. Murphy SB, Morgan ER, Katzenstein HM, et al. Results of little for not treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol. 2003;25:684–7.

    Article  PubMed  Google Scholar 

  29. Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J. 2002;8:377–83.

    Article  PubMed  Google Scholar 

  30. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104:1221–9.

    Article  PubMed  Google Scholar 

  31. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16:1683–7.

    Article  PubMed  CAS  Google Scholar 

  32. Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38 suppl 4:107–13.

    Article  Google Scholar 

  33. JNCCN – The Journal of the National Comprehensive Cancer Network. 2008;6(6) http://www.nccn.org/JNCCN/toc/2008jul.asp#hodgkins

  34. Feugier P, Labouyrie E, Djeridane M, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood. 2004;104:2675–81.

    Article  PubMed  CAS  Google Scholar 

  35. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28:136–41.

    Article  PubMed  Google Scholar 

  36. Fanale MA, Younes A. Nodular lymphocyte predominant Hodgkin’s lymphoma. Cancer Treat Res. 2008;142:367–81.

    PubMed  Google Scholar 

  37. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Study Group. Blood. 2003;101:420–4.

    Article  PubMed  CAS  Google Scholar 

  38. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101:4285–9.

    Article  PubMed  CAS  Google Scholar 

  39. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of Ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial. Blood. 2008;111:5486–95.

    Article  PubMed  CAS  Google Scholar 

  40. Popat U, Hosing C, Fanale M, et al. Autologous transplantation for nodular lymphocyte-predominant Hodgkin lymphoma (LPHL). Blood (ASH Annual Meeting Abstracts) 2009;114:2310.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, University Hospital of Cologne, Kerpener Strasse 62, 50924, Köln, Germany

    Andreas Engert

  2. Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Anas Younes

Authors
  1. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anas Younes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Engert .

Editor information

Editors and Affiliations

  1. Klinik I für Innere Medizin, Universität Köln, Joseph-Stelzmann-Str. 9, Köln, 50924, Germany

    Andreas Engert

  2. Dept. Medicine, Stanford University, Stanford, 94305-5479, California, USA

    Sandra J. Horning

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Engert, A., Younes, A. (2011). Lymphocyte-Predominant Hodgkin Lymphoma. In: Engert, A., Horning, S. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12780-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12780-9_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12779-3

  • Online ISBN: 978-3-642-12780-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation